Johnson & Johnson has asked its coronavirus vaccine competitors Pfizer, Moderna and AstraZeneca to jointly investigate post-vaccination thrombosis, according to the Wall Street Journal.
According to the American publication, AstraZeneca, which is now at the center of the thrombosis scandal, was the only one to respond positively. Instead, Pfizer and Moderna refused, saying they considered their vaccines safe.
According to the report, Johnson & Johnson came into contact with its competitors after investigating US thrombosis cases, which eventually led to a “freeze” of its use by the US authorities, at least for a while, according to the report.
However, both Pfizer and Moderna objected because they did not find reasons to participate in the investigation, which had already been launched by the authorities, regarding the thrombosis cases and the reasons that caused them, since they did not observe thrombosis in anyone vaccinated with their vaccine.
The Johnson & Johnson coronavirus vaccine will not be used for vaccinations from Monday, as previously scheduled, as the Secretary General of Primary Health Care Marios Themistokleous said on April 16, although Greece has already received more than 30,000 doses of the vaccine.
“This vaccine will not be vaccinated until we receive more recent information from the EMA,” he explained, stressing that no specific vaccine prescriptions have been assigned. Regarding the AstraZeneca vaccine, he explained that the problem was due to various decisions taken by European countries, but the scientific evidence is clear. That is, the benefits of vaccination outweigh the lack of vaccination and the risks of contracting Covid. “We see that a large percentage of those who made an appointment for the AstraZeneca vaccination did not cancel it,” added Mr. Themistokleous, stressing that the vaccination program will continue as usual.